Intravenous Immunoglobulins
Mostrando 13-24 de 35 artigos, teses e dissertações.
-
13. Toxoplasma gondii-Associated Guillain-Barré Syndrome in an Immunocompetent Patient
We report a case of Guillain-Barré syndrome associated with an acute, disseminated toxoplasmosis due to a new and unknown zymodeme (zymodeme 12) in an immunocompetent patient. The patient’s condition improved with pyrimethamine and sulfadiazine. Only the standard treatment for toxoplasmosis was effective, whereas intravenous immunoglobulins were ineffecti
American Society for Microbiology.
-
14. Relapse of chronic inflammatory demyelinating polyneuropathy 5 years after autologous stem cell transplantation
We describe relapse of chronic inflammatory demyelinating polyneuropathy in a patient who had been in remission for 5 years after treatment with autologous stem cell transplantation. Before the transplant, he needed higher doses of immunosuppressive treatment than are now necessary to maintain his improved condition. He now receives intravenous immunoglobu
BMJ Group.
-
15. Chronic inflammatory demyelinating polyneuropathy associated with carcinoma.
The association of chronic inflammatory demyelinating polyneuropathy (CIDP) and carcinoma has rarely been reported and its relevance is debated. Thirty three consecutive patients with probable or definite CIDP (idiopathic or associated with M protein) were investigated. Three patients with definite CIDP had a concomitant carcinoma. One had an IgM paraprotein
-
16. Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: effects on disease activity and serum cytokines.
OBJECTIVE--To evaluate the effects of long term treatment of rheumatoid arthritis (RA) with high doses of intravenous immunoglobulins (IVIg). METHODS--Ten patients with active RA and prior unsuccessful treatment with at least one slow acting antirheumatic drug were treated with 400 mg/kg of IVIg for the first three days and then once a month for 12 months. C
-
17. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study.
The effect of high dose intravenous immunoglobulin (IVIg) treatment was studied in six patients with multifocal motor neuropathy (MMN). All patients responded to treatment (0.4 g/kg for five consecutive days) in an open trial. The effect of IVIg treatment was confirmed for each patient in a single patient, double blind, placebo controlled trial. Four patient
-
18. Medical and surgical management of spontaneous hyphaema secondary to immune thrombocytopenia.
The medical and surgical management of an unusual case of spontaneous 'black ball' hyphaema complicated by secondary haemorrhage, raised intraocular pressure and corneal blood staining, and secondary to immune thrombocytopenia is presented. The literature is reviewed with particular reference to the aetiology and treatment of spontaneous hyphaema and the rol
-
19. Effect of fresh frozen plasma and gammaglobulin on humoral immunity in neonatal sepsis.
Fresh frozen plasma and intravenous immunoglobulin are used as prophylaxis against, and for the treatment of, neonatal infection. It is assumed that any beneficial effect is mediated through the humoral immune factors contained in each preparation. The effect of fresh frozen plasma and intravenous immunoglobulin on humoral immune markers (immunoglobulins and
-
20. Clinical experience with Flebogamma® 5% DIF: a new generation of intravenous immunoglobulins in patients with primary immunodeficiency disease
The development of effective, safe, liquid intravenous immunoglobulins (IVIG) preparations has represented a major therapeutic advancement in the treatment of patients with antibody deficiencies. Flebogamma® 5% was the first liquid IVIG licensed in Europe that has been widely used in the treatment of immunodeficiency diseases. It has been proven to have an
Blackwell Science Inc.
-
21. Influence of immunoglobulin and interleukin 2 on the translocation of microorganisms from gut into blood.
The aim of this study was to influence the translocation of microorganisms and endotoxin from the gut of septic rats by the intravenous (i.v.) administration of immunoglobulin and interleukin 2. Acute infection was induced in all animals by an intraperitoneal bacterial challenge of 2 x 10(6) microorganisms (Ps. aeruginosa, E. coli, Kleb. pneumoniae). Immedia
-
22. High dose immunoglobulin IV treatment in adrenoleukodystrophy.
X-linked adrenoleukodystrophy (ALD) is an inborn error of peroxisomal metabolism characterised by progressive demyelination of the central nervous system and by hypoadrenalism. The biochemical defect of ALD results in an impairment in degradation of very long chain fatty acids (VLCFA) with their accumulation in plasma and tissues. Many therapeutic approaches
-
23. Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial.
No treatment has been found which reverses long-standing neurological dysfunction in patients with multiple sclerosis (MS). Observations in animal models of MS show that immunoglobulins directed against CNS components promote oligodendroglial proliferation and new myelin synthesis. Preliminary studies in inflammatory-demyelinating diseases of the human perip
-
24. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange.
Since the introduction of plasma exchange as a treatment for Guillain-Barré syndrome (GBS) patients, treatment related fluctuations have been found to occur in about 10% of the patients. These fluctuations are considered additional evidence of the beneficial effect of plasma exchange. In this report the occurrence of such treatment related fluctuations is d